The first antibody-photosensitizer conjugate (APC) of world is RM-1929, an antibody cetuximab targeting epidermal growth factor receptor (EGFR)-conjugated PS IR700, was approved for marketing in Japan in September 2020 for the treatment of head and neck squamous cell carcinoma. Here, EGFR is linked to head and neck squamous cell carcinoma.